Today, ACI joined over two dozen groups in sending a letter to Congress in support of legislation that would increase competition for biologic drugs as a means to lower drug prices for patients. On behalf of millions of patients, providers, and taxpayers, we strongly support promoting the use of affordable and safe biosimilars across the country.
The letter is available here.